SS-31 Peptide Protocol: Dosing, Routes, and Safety

An SS-31 peptide protocol is the planned combination of route, dose, frequency, and monitoring used with SS-31 (elamipretide), a mitochondria-targeted tetrapeptide. In published human trials, the most common approach has been a once-daily subcutaneous injection of 40 mg for 12 weeks or longer, while some heart failure studies used intravenous infusions instead. SS-31 is not FDA-approved for general human use in the United States, so any protocol followed outside a clinical trial is experimental.

What Is SS-31 (Elamipretide)?

SS-31 is a synthetic four-amino-acid peptide also known as elamipretide, MTP-131, and Bendavia. It was designed to concentrate in the inner mitochondrial membrane, where it binds to cardiolipin and helps stabilize the electron transport chain.

That mechanism is why SS-31 is studied in conditions linked to mitochondrial dysfunction, including Barth syndrome, primary mitochondrial myopathy, heart failure, dry age-related macular degeneration, and ischemia-reperfusion injury. It is not a hormone, and it is not structurally related to growth-hormone secretagogues.

How a Typical SS-31 Peptide Dosing Protocol Is Built

Anyone researching an ss-31 peptide dosing protocol needs to answer four questions: how the peptide is given, how much is given, how often, and for how long. Trial protocols have varied mainly by condition and by whether the drug was delivered at home or in a hospital.

Study setting	Route	Reported dose	Frequency
Barth syndrome (TAZPOWER)	Subcutaneous	40 mg	Once daily, up to 24 weeks
Primary mitochondrial myopathy (MMPOWER)	Subcutaneous	40 mg	Once daily, 12 weeks
Dry AMD (ReCLAIM)	Subcutaneous	40 mg	Once daily, 12 weeks
Heart failure trials	Intravenous infusion	Protocol-specific	Short in-hospital infusions
Preclinical animal work	Subcutaneous or intraperitoneal	Weight-based (mg/kg)	Varies by study

When people search for an ss-31 peptide dosage, they usually want a single number. The honest answer is that no universal dose exists: subcutaneous research doses have clustered around 40 mg per day in adults, while infusion studies used milligram-per-kilogram rates that only make sense under medical supervision.

Subcutaneous vs. Intravenous Delivery

Factor	Subcutaneous	Intravenous
Typical setting	Outpatient or at-home trial visits	Hospital or infusion clinic
Absorption	Slower and more gradual	Immediate and complete
Main practical issue	Injection site reactions	IV access and monitoring
Common in research for	Chronic conditions	Acute cardiac events

Reported Benefits and Side Effects

Results from SS-31 trials have been mixed rather than dramatic. A phase 3 trial in primary mitochondrial myopathy missed its primary endpoint, although a pre-specified subgroup showed improvement on the six-minute walk test. Open-label Barth syndrome data have suggested gains in some functional measures, and dry AMD studies have reported changes in retinal structure.

Reported ss-31 peptide side effects have generally been mild in trials. The most frequently documented issues include:

• Injection site reactions such as redness, pain, or swelling
• Headache
• Nausea
• Dizziness or lightheadedness
• Fatigue

Long-term safety data are limited. Nobody knows the effects of months or years of self-administered SS-31 outside a monitored trial, and anyone considering it should talk with a healthcare professional first.

SS-31 and MOTS-c: What a Stacking Protocol Looks Like

MOTS-c is a mitochondrial-derived peptide that influences metabolic signaling, and some researchers pair it with SS-31 in what is often described as an ss-31 and mots-c protocol. The logic is that both compounds act on mitochondrial function, so combining them might address energy production and metabolic regulation at the same time.

That logic is theoretical. No published human trial has tested SS-31 and MOTS-c together, and there is no data on how they interact, what a combined dose would be, or whether the combination is safe. Stacking two unapproved peptides multiplies the unknowns rather than reducing them.

SS-31 in Bodybuilding and Performance Circles

Interest in ss-31 peptide bodybuilding comes mostly from animal studies and internet anecdotes rather than athlete trials. SS-31 does not build muscle the way anabolic compounds do; the proposed benefit is better mitochondrial efficiency, which some users hope will translate into endurance and faster recovery.

There is no human performance data to support those claims. A glowing personal account should be treated as an anecdote, not evidence, and most products sold for this purpose are labeled for research use only.

Legal Status, Sourcing, and Safety

SS-31 is not FDA-approved for human use in the United States. It cannot legally be sold as a dietary supplement, and compounding pharmacies are not permitted to compound it for general patient use.

Because of that, most SS-31 sold online is marketed as a research chemical. Purity, sterility, and actual peptide content are not verified by any regulator, and independent testing of research peptides has repeatedly found vials that did not match their labels. A certificate of analysis from the seller is not the same as third-party verification.

Monitoring Checklist for Anyone Considering SS-31

1. Review your medical history, medications, and allergies with a licensed clinician.
2. Get baseline blood work, including a complete blood count, metabolic panel, and liver and kidney function tests.
3. Record the dose, time, and injection site for every administration.
4. Track injection site reactions and any new symptom, no matter how minor it seems.
5. Avoid combining SS-31 with other experimental peptides unless a clinician is supervising.
6. Stop and seek medical care for chest pain, shortness of breath, severe headache, or signs of infection at an injection site.

Key Takeaways

• SS-31 is not FDA-approved for human use in the United States.
• The most commonly reported SS-31 dose in human trials is 40 mg given subcutaneously once daily.
• No published human trial has tested SS-31 combined with MOTS-c.
• SS-31 is not a muscle-building peptide, and no human study has measured its effect on muscle growth in athletes.
• Reported side effects in trials were mostly mild, but long-term safety remains unknown.

COMMON QUESTIONS

Frequently Asked Questions

Is the SS-31 peptide FDA-approved?

No. SS-31 (elamipretide) is not FDA-approved for human use in the United States, and it cannot legally be sold as a dietary supplement. It remains an investigational drug available only through clinical trials or as a research chemical labeled for laboratory use.

What is the typical SS-31 peptide dosage?

The most commonly reported dose in human trials is 40 mg injected subcutaneously once daily, usually for 12 weeks or longer. Heart failure trials used intravenous infusions at protocol-specific rates. There is no standard dose for people using SS-31 outside of a clinical trial.

What side effects has SS-31 been linked to?

Trial reports most often describe injection site reactions such as redness, pain, or swelling, along with headache, nausea, dizziness, and fatigue. Most reported events were mild, but long-term safety data are limited because SS-31 has not been studied for years at a time in large populations.